Protein identified that can result in fragile bones

Too little of a protein called neogenin results in a smaller skeleton during development and sets the stage for a more fragile bone framework lifelong, Medical College of Georgia researchers report.

A developing mouse with neogenin deficits has poorly defined digits and is generally smaller, including having small growth plates, an indicator of future development, said Dr. Wen-Cheng Xiong, developmental neurobiologist in the MCG Schools of Medicine and Graduate Studies and corresponding author of the study published in Developmental Cell. Dr. Zheng Zhou, MCG assistant research scientist, is first author.

Their findings provide new insight into skeletal development as they point toward a potential new direction for treating osteoarthritis, a common, painful and debilitating condition where cartilage between bones is lost, Xiong said.

Neogenin doesn't make bone; rather, it forms a protein complex essential to turning on cartilage-producing genes, the researchers found. "Each cell type has a master gene. Neogenin is not that, it's more of a modulator," Xiong said. That's why, if it's mutated, like in the mouse, cartilage and bone formation is disrupted - not halted. It's also why neogenin could be a good therapeutic target for turning the tide on cartilage or bone loss that occurs in osteoarthritis, Xiong said.

Skeletal development occurs early, which is why pregnant women need so much calcium. Initially the skeleton consists of soft bone or cartilage, which attracts blood vessels as well as the osteoblasts that replace most cartilage with hard bone over time. After birth, growth plates, where hard and soft bone meet, enable bones to lengthen and children to grow. After puberty, growth plates go away and bone hardens except for cartilage at the joints that eases movement and provides cushion. While bone cells continue to turn over, bone growth and loss should balance each other out after puberty due to osteoclasts - cells that break down and resorb bone. Diseases such as osteoporosis and osteoarthritis occur when osteoclasts start winning. Nutrition, inflammation and hormones are among the many factors that impact bone's status.

Neogenin, which Xiong has shown helps direct neurons during brain development and aid in regulation of iron levels, is found throughout bone and cartilage and numerous other tissues. Its pervasiveness reflects its many functions, depending on the stage of life and location, she noted.

Xiong suspects the protein has multiple roles in adulthood as well, albeit slightly different ones. In adulthood, neogenin may become more of an overseer, keeping tabs on functions it influences, such as bone formation. It resumes an instigator role when something goes amiss.

"Every function in the body needs to be able to go up or down," Xiong said, noting that neogenin pathways are likely altered in disease. "I think in the disease condition this molecule could be changed. The pathways are altered, not eliminated, rather increased or decreased abnormally."

Treating problems such as osteoporosis, iron overload and anemia, would require drugs that could keep protein levels high. Meanwhile, she wants to confirm neogenin's influence on cartilage function in adulthood. "In late-stage arthritis, the cartilage function may be completely disrupted but early in the disease process, maybe there is a window for stimulating this protein."